🔓 Unlock the full profile of Jeffrey Engelman (Treeline Biosciences), including verified contact details, financial insights, and professional associations.
See Jeffrey Engelman Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: jef*****@tre******.com
Mobile: 89346*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Jeffrey Engelman currently serves as the Chief Scientific Officer (CSO) and Co-Founder of Treeline Biosciences, an organization founded in April 2021, focused on innovative approaches in drug discovery.
- Prior to Treeline, Engelman held the position of Global Head of Oncology at Novartis Institutes for BioMedical Research from June 2016 until April 2021, where significant advancements in oncology research were achieved.
- Engelman contributed to Mass General Hospital from 2007 to 2016, where roles included Director of Thoracic Oncology, Director of Molecular Therapeutics, and Principal Investigator in a laboratory setting, emphasizing the integration of molecular biology in cancer therapeutics.
- Engelman completed a Hematology/Oncology Fellowship at Dana-Farber Cancer Institute from 2003 to 2005, further strengthening expertise in cancer treatments and research.
- During the tenure at Mass General Hospital, Engelman led multidisciplinary teams to drive clinical trial initiatives and contributed to advancements in understanding lung cancer genetics.
- The leadership role in Treeline Biosciences involves steering scientific strategy, collaborating with various stakeholders, and fostering a culture of innovation to address unmet medical needs in oncology.
- Engelman has established a reputation in the scientific community for expertise in translational medicine and developing novel therapies for cancer.
- Engelman has also been involved in mentoring emerging scientists and fostering educational programs within the biomedical field, enhancing community engagement and knowledge sharing.